ALLO
Allogene Therapeutics, Inc.Company with tickers: ALLO
Market Cap
$711.02M
Shares Outstanding
345,154,561
CIK
1737287
CUSIP
019770106
13F Activity (30d)
2 filings
1 filers
Website
Visit website
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Zachary Roberts, M.D., Ph.D. | Class I director | Appointed | 2026-05-28 |
| Zachary Roberts, M.D., Ph.D. | President and Chief Executive Officer | Appointed | 2026-05-28 |